The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...
First patient dosed in Opti-GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMD CTx001 is an investigational AAV-based gene therapy designed to deliver ...
Researchers identify bone-forming cells as the driver of scoliosis caused by a genetic disorder, which can be prevented by medications. CHINA, January 14, 2026 ...
Cedars-Sinai investigators have identified a genetic variant that increases people's risk of developing perianal Crohn's disease, the most debilitating manifestation of Crohn's disease. Science X ...
Nivolumab combined with AVD demonstrated superior progression-free survival compared with brentuximab vedotin with AVD in advanced classical Hodgkin lymphoma (cHL). The SWOG S1826 trial showed a ...
The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results